Category: imidazoles-derivatives

Singh, Gagandeep published the artcileSynthesis, molecular docking, α-glucosidase inhibition, and antioxidant activity studies of novel benzimidazole derivatives, SDS of cas: 4760-35-4, the publication is Medicinal Chemistry Research (2020), 29(10), 1846-1866, database is CAplus.

A novel series of N-methyl/benzyl-substituted benzimidazolyl-linked para-substituted benzyl-based compounds containing 2,4-thiazolidinediones, di-Me malonate (DMM) and di-Et malonate (DEM) were designed, docked, synthesized, and evaluated for their antidiabetic activity studies. Four targeted compounds I (R = Me, Bn) and II showed good inhibitory potential in the range of 4.10 +/- 0.01 to 9.12 +/- 0.06μM. Furthermore, synthesized compounds were evaluated for their antioxidant potential and compared with standard ascorbic acid and results showed that compound I (R = Bn) (EC₅₀ = 0.176 +/- 0.002 mM) being the most active. Compounds I and II exhibited prominent antidiabetic as well as antioxidant activity. Compound I (R = Bn) was considered a promising candidate for this series. The designed mols. were docked into α-glucosidase protein (PDB Code. 3TOP) to develop a correlation with the α-glucosidase inhibition studies and were also addnl. docked into PPARγ proteins (PDB ID: 2PRG) with rosiglitazone (standard drug) to study their PPARγ binding affinity in comparison with rosiglitazone and to classify these compounds for their PPARγ agonistic behavior.

Medicinal Chemistry Research published new progress about 4760-35-4. 4760-35-4 belongs to imidazoles-derivatives, auxiliary class Chloride,Benzimidazole, name is 2-(Chloromethyl)-1-methyl-1H-benzo[d]imidazole, and the molecular formula is C25H29N9O3, SDS of cas: 4760-35-4.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Pathak, Devender published the artcileSynthesis, characterization and antimicrobial evaluation of some newer substituted benzimidazole derivatives, SDS of cas: 4760-35-4, the publication is Journal of Chemical and Pharmaceutical Sciences (2011), 4(1), 26-29, database is CAplus.

1,2-Benzenediamine dihydrochloride when reacted with different carboxylic acid derivatives yielded 2-substituted benzimidazole derivatives [no data] which on methylation afforded 1-methyl-2-substituted benzimidazole derivatives, and on acetylation yielded 1-acetyl-2-substituted benzimidazole derivatives The synthesized compounds were elucidated by phys. and spectral data and screened for in vitro antibacterial activity against two gram pos. (Staphylococcus aureus, Bacillus subtilis) and two gram neg. bacterial strains (Pseudomonas aeruginosa, Escherichia coli) and in vitro antifungal activity against Candida albicans, Aspergillus niger.

Journal of Chemical and Pharmaceutical Sciences published new progress about 4760-35-4. 4760-35-4 belongs to imidazoles-derivatives, auxiliary class Chloride,Benzimidazole, name is 2-(Chloromethyl)-1-methyl-1H-benzo[d]imidazole, and the molecular formula is C9H9ClN2, SDS of cas: 4760-35-4.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Artemenko, M. V. published the artcileComplexes of copper salts with 2-(hydroxymethyl)benzimidazole and 1-methyl-2-(hydroxymethyl)benzimidazole, Recommanded Product: (1-Methyl-1H-benzo[d]imidazol-2-yl)methanol, the publication is Ukrainskii Khimicheskii Zhurnal (Russian Edition) (1966), 32(6), 560-6, database is CAplus.

2-(Hydroxymethyl)benzimidazole (ROH) and 1-methyl-2-(hydroxymethyl)benzimidazole (R’OH) react with Cu salts and an equimolar amount of PhNMe₂ in MeOH to form the following compounds (formula and m.p. given): ROCuCl, 216°; ROCuBr, 196°; R’OCuCl, 224°; R’ OCuBr, 223°; R’ OCuONO₂, 231°. The following were prepared by grinding together and adding MeOH or by mixing solutions of the components in MeOH solution: ROCuOAc, over 300°; R’ OCuOAe, 219°; 2ROH.Cu(NO₃)₂. MeOH (heating to 80° forms 2ROH. Cu(NO₃)₂, m. 203°); 2ROH.CuSO₄, over 250°; 3ROH.CuSO₄, over 250°; R’ OH.R’ OCuCl, 178°; R’ OH.R’ OCuBr, 196°; R’ OH.R’ OCuONO₂, 218°; 2R’ OH.Cu(NO₃)₂, 172°; 3R’OH.CuSO₄, 154°. ROH and CuSO₄ form ROH.CuSO₄4H₂O, m. 234°, in H₂O solution Dehydration yields ROH.-CuSO₄, m. 234°. Salts of ROH and R’ OH after grinding with Cu salts, solution in MeOH, and precipitation with Et₂O, form (ROH₂)₂(CuBr₄), m. 126°; (R’ OH₂)₂(CuCl₄), m. 166°; and (R’ OH₂)₂(CuBr₄), m. 158°. R’OH and Cu(OCH₂CH₂NH₂)₂ (CA 59, 8340h) in MeOH form R’ OCuOH, m. 142°.

Ukrainskii Khimicheskii Zhurnal (Russian Edition) published new progress about 7467-35-8. 7467-35-8 belongs to imidazoles-derivatives, auxiliary class Benzimidazole,Alcohol, name is (1-Methyl-1H-benzo[d]imidazol-2-yl)methanol, and the molecular formula is C9H10N2O, Recommanded Product: (1-Methyl-1H-benzo[d]imidazol-2-yl)methanol.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Artemenko, M. V. published the artcileComplex formation in the cupric nitrate-1-methyl-2-(hydroxymethyl)benzimidazole-methanol system, Synthetic Route of 7467-35-8, the publication is Zhurnal Neorganicheskoi Khimii (1967), 12(11), 3055-61, database is CAplus.

The complex formation of Cu(NO3)2 with 1-methyl-2-(hydroxymethyl)benzimidazole (I) in MeOH was studied by means of various optical methods. Four complex compounds, 2 addition products with the molar ratio of Cu:I = 1:1 and 1:3 and the other 2 mixed chelate alcoholates with 1:1 and 1:2 composition, were found. On the basis of the anal. the absorption spectra of the isomolar series of the solutions were decomposed into sep. Gaussian components. The application of crystal field theory established that these complex compounds have a tetragonal bipyramidal configuration. The optical characteristics for the detected bands of these complex compounds are given. The Me group in the 1 position in the I mol. has no influence on the composition and optical characteristics of the complex compounds

Zhurnal Neorganicheskoi Khimii published new progress about 7467-35-8. 7467-35-8 belongs to imidazoles-derivatives, auxiliary class Benzimidazole,Alcohol, name is (1-Methyl-1H-benzo[d]imidazol-2-yl)methanol, and the molecular formula is C9H10N2O, Synthetic Route of 7467-35-8.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Alasmary, Fatmah A. S. published the artcileSynthesis and evaluation of selected benzimidazole derivatives as potential antimicrobial agents, Quality Control of 7467-35-8, the publication is Molecules (2015), 20(8), 15206-15223, database is CAplus and MEDLINE.

A library of 53 benzimidazole derivatives, with substituents at positions 1, 2 and 5, were synthesized and screened against a series of reference strains of bacteria and fungi of medical relevance. The SAR analyses of the most promising results showed that the antimicrobial activity of the compounds depended on the substituents attached to the bicyclic heterocycle. In particular, some compounds displayed antibacterial activity against two methicillin-resistant Staphylococcus aureus (MRSA) strains with min. inhibitory concentrations (MICs) comparable to the widely-used drug ciprofloxacin. The compounds had some common features; three possess 5-halo substituents; two were derivatives of (S)-2-ethanaminebenzimidazole; and the others were derivatives of one 2-(chloromethyl)-1H-benzo[d]imidazole and (1H-benzo[d]imidazol-2-yl)methanethiol. The results from the antifungal screening were also very interesting: 23 compounds exhibited potent fungicidal activity against the selected fungal strains. They displayed equivalent or greater potency in their MIC values than amphotericin B. The 5-halobenzimidazole derivatives were considered as promising broad-spectrum antimicrobial candidates that deserve further study for potential therapeutic applications.

Molecules published new progress about 7467-35-8. 7467-35-8 belongs to imidazoles-derivatives, auxiliary class Benzimidazole,Alcohol, name is (1-Methyl-1H-benzo[d]imidazol-2-yl)methanol, and the molecular formula is C9H10N2O, Quality Control of 7467-35-8.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Chen, Zicong published the artcilePd-Catalyzed Cross-Coupling of Highly Sterically Congested Enol Carbamates with Grignard Reagents via C-O Bond Activation, COA of Formula: C27H39ClN2, the publication is Organic Letters (2020), 22(10), 3879-3883, database is CAplus and MEDLINE.

The palladium-catalyzed cross-coupling reaction of enol carbamates to construct highly sterically congested alkenyl compounds was presented for the first time. This protocol demonstrated the potential of using thermally stable and highly atom-economic enol electrophiles as building blocks in bulky alkene synthesis. This reaction accommodates a broad substrate scope with excellent Z/E isomer ratios, which also provided a new synthetic pathway for accessing Tamoxifen.

Organic Letters published new progress about 258278-25-0. 258278-25-0 belongs to imidazoles-derivatives, auxiliary class Achiral NHCs Ligands, name is 1,3-Bis(2,6-diisopropylphenyl)-4,5-dihydro-1H-imidazol-3-ium chloride, and the molecular formula is C27H39ClN2, COA of Formula: C27H39ClN2.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Yang, Ke published the artcileThe decarboxylative C-H heteroarylation of azoles catalysed by nickel catalysts to access unsymmetrical biheteroaryls, Quality Control of 258278-25-0, the publication is Organic Chemistry Frontiers (2019), 6(24), 3996-3999, database is CAplus.

A series of unsym. biheteroaryls R-R¹ [R = benzoxazol-2-yl, 4-Ph-oxazol-2-yl, 6-Cl-benzoxazol-2-yl, etc.; R¹ = 2-furyl, 2-thienyl, 3-Me-benzofuran-2-yl, etc.] via nickel-catalyzed direct decarboxylative C-H heteroarylation of azoles with heteroaryl carboxylic acids was reported.

Organic Chemistry Frontiers published new progress about 258278-25-0. 258278-25-0 belongs to imidazoles-derivatives, auxiliary class Achiral NHCs Ligands, name is 1,3-Bis(2,6-diisopropylphenyl)-4,5-dihydro-1H-imidazol-3-ium chloride, and the molecular formula is C8H8O3, Quality Control of 258278-25-0.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Butera, John A. published the artcileSynthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives, Category: imidazoles-derivatives, the publication is Journal of Medicinal Chemistry (1991), 34(11), 3212-28, database is CAplus and MEDLINE.

The synthesis and biol. evaluation of a series of novel 1-(aryloxy)-2-propranolamines and several related deshydroxy analogs are described. The compounds were prepared and investigated for their class III electrophysiol. activity in isolated canine Purkinje fibers and in anesthetized open-chest dogs. None of these compounds showed any class I activity. On the basis of the in vitro data, structure-activity relations for the series are discussed. Two compounds, WAY-123,223 (I) and WAY-125,971 (II) were identified and characterized as potent and specific class III antiarrhythmic agents in vitro and in vivo. I was orally bioavailable, to produce large increases of ventricular fibrillation threshold (VFT), and, in some instances, to restore sinus rhythm from ventricular fibrillation in anesthetized open-chest dogs at a dose of 5 mg/kg (i.v.). The enantiomers of I were synthesized and found to exhibit similar electrophysiol. effects in the Purkinje fiber screen. II, a propylamine analog with potency and efficacy comparable to those of UK-68798 and E-4031, was studied in voltage-clamp experiments (isolated cat myocytes) and found to be a potent and specific blocker of the delayed rectifier potassium current (I_K).

Journal of Medicinal Chemistry published new progress about 4760-35-4. 4760-35-4 belongs to imidazoles-derivatives, auxiliary class Chloride,Benzimidazole, name is 2-(Chloromethyl)-1-methyl-1H-benzo[d]imidazole, and the molecular formula is C9H9ClN2, Category: imidazoles-derivatives.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Subbaiah, B. Venkata published the artcilePREPARATIVE ISOLATION AND UPLC-TOF MS IDENTIFICATION OF EIGHT DEGRADANTS FROM STRESSED TABLETS OF ESOMEPRAZOLE, Application In Synthesis of 161796-78-7, the publication is Journal of Liquid Chromatography & Related Technologies (2013), 36(9), 1243-1250, database is CAplus.

Esomeprazole is a proton pump inhibitor, used in the treatment peptic ulcer disease (PUD). Eight degradants were found in the formulated drug under the stress conditions, (40°C/75% Relative Humidity (RH) for 6 mo) with Relative Retention Time’s (RRT’s) 0.26, 0.29, 0.32, 0.59, 0.88, 0.96, 1.12, and 1.33 by a LC-MS compatible method. A simple effective gradient preparative HPLC method was developed with the runtime of 20 min to isolate all the degradants. The degradants were stabilized and identified by UPLC-TOF MS. The method is capable and can be used to isolate further degradants. Supplemental materials are available for this article. Go to the publisher’s online edition of Journal of Liquid Chromatog. and Related Technologies to view the free supplemental file.

Journal of Liquid Chromatography & Related Technologies published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C11H21BF4N2O2, Application In Synthesis of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Kumar, Y. Naveen published the artcileFormulation development of controlled release formulation of esomeprazole sodium tablets, HPLC of Formula: 161796-78-7, the publication is Indo American Journal of Pharmaceutical Sciences (2015), 2(5), 955-960, database is CAplus.

The main aim of this work is Esomeprazole sodium is formulated as controlled release tablets to provide desired effect at certain time in maintained drug concentration without any unwanted effect with patient compliance also to improve it bioavailability by decreasing its expose to gastric acid. A controlled release dosage form is designed to release the drug from the dosage form at a time other than promptly after administration. UV Spectrophotometric method has been developed for the estimation of Esomeprazole in pharmaceutical formulations. Then the tablets were prepared by dry granulation method rather than direct compression because of cohesive property of the drug. Optimized core tablet then subjected for enteric coating by selected base coat polymer cellulose derivative for preventing core tablet from moisture. The coated formulations were compared with marketed sample (ESOZ) for optimization. Dissolution results of tablets with enteric coating have shown release of Esomeprazole in simulated gastrointestinal fluid pH 1.2, but most of the drug released in pH 6.8 Phosphate buffer. At the end it was found that prepared formulation gave satisfactory results compared with marketed sample dissolution profile. Hence prepared formulation bypass the degradation of Esomeprazole by enteric coating approach and can be used as single unit dosage for the treatment of acid-related diseases. Thus a pharmaceutically equivalent, robust formulation of Esomeprazole controlled release tablet was developed.

Indo American Journal of Pharmaceutical Sciences published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, HPLC of Formula: 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem